Cover Image
市場調查報告書

EpiCast Report:前列腺癌的流行病學的預測 (∼2023年)

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 331730
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:前列腺癌的流行病學的預測 (∼2023年) EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2023
出版日期: 2015年04月06日 內容資訊: 英文 52 Pages
簡介

全球主要9個國家(美國、法國、德國、義大利、西班牙、英國、日本、巴西、加拿大) 的前列腺癌的診斷病例數,預計從2013年到2023年以3.60%的年齡成長率推移,從2013年的813,462件至2023年達到1,106,349件。還有主要9個國家5年的累積患病人數,預計從2013年的3,381,581件到2023年以3.66%的年成長率擴大到4,618,451件。

本報告提供全球主要9個國家前列腺癌的診斷病例數及死亡人數變化的相關調查、疾病的背景、風險要素和並存症、各年齡、性別、重症度、原因病原的診斷病例數及死亡人數的預測等相關彙整。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 風險要素與並存症
  • 全球趨勢
    • 美國
    • 歐盟5國
    • 日本、巴西、加拿大
  • 預測手法
    • 使用來源
    • 未使用來源
    • 預測的前提條件、手法
  • 前列腺癌的流行病學的預測
    • 診斷病例數
    • 診斷病例數:各年齡
    • 標準診斷案例:各年齡
    • 診斷的分期
    • 5年的患病人數
    • 5年的患病人數:CRPC
    • 5年的患病人數:CRPC患者的骨骼轉移
  • 檢驗
    • 流行病學的預測的考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

  • 參考資料
  • 關於作者
  • 關於GlobalData
  • 關於EpiCast
  • 免責聲明

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER079-15

Prostate cancer is a malignant tumor that forms in the tissues of the prostate, a gland in the male reproductive system found below the bladder and in front of the rectum. Although prostate cancer cases have been reported in all age groups, the majority of cases occur in men over the age of 65 years. Prostate cancer is the second most common cancer in men worldwide. An estimated 1.1 million men worldwide were diagnosed with prostate cancer in 2012, accounting for 15% of all the cancers diagnosed in men (IARC, 2014).

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for prostate cancer in the nine major markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada). It includes a 10-year epidemiological forecast for the diagnosed incident cases of prostate cancer segmented by age (in 10-year age groups beginning at age 40 years and ending at age =85 years) in these markets.

In 2013, there were a total of 813,462 diagnosed incident cases of prostate cancer in the 9MM. GlobalData epidemiologists forecast that the diagnosed incident cases in the 9MM will increase to 1,106,349 cases by 2023 at an Annual Growth Rate (AGR) of 3.60%. All markets will see an increase in the number of cases, with AGRs ranging from 0.71% (Germany) to 8.66% (Brazil). The 9MM had an estimated 3,381,581 diagnosed five-year prevalent cases of prostate cancer in 2013. The number of diagnosed five-year prevalent cases will increase over the next decade to 4,618,451 diagnosed prevalent cases by 2023 at an AGR of 3.66%.

Brazil appears to be a market of concern, with a rapidly increasing incidence and prevalence of prostate cancer. GlobalData epidemiologists calculated that Brazil will have the highest AGR in diagnosed incident cases among the 9MM (8.66%), as well as the highest AGR in five-year diagnosed prevalent cases (8.98%).

Scope

  • The Prostate Cancer EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for prostate cancer in the nine major markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada). It includes a 10-year epidemiological forecast for the diagnosed incident cases of prostate cancer segmented by age (in 10-year age groups beginning at age 40 years and ending at age =85 years) and clinical stage at diagnosis in these markets. The report also provide a forecast for the diagnosed five-year prevalent cases of prostate cancer segmented by castration resistance status and bone metastases status.
  • The prostate cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global prostate cancer market.
  • Quantify patient populations in the global prostate cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and clinical stage at diagnosis that present the best opportunities for prostate cancer therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Report

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan, Brazil, and Canada
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for Prostate Cancer (2013-2023)
    • 3.5.1. Diagnosed Incident Cases of Prostate Cancer
    • 3.5.2. Age-Specific Diagnosed Incident Cases of Prostate Cancer
    • 3.5.3. Age-Standardized Diagnosed Incidence of Prostate Cancer
    • 3.5.4. Clinical Stage at Diagnosis
    • 3.5.5. Diagnosed Five-Year Prevalent Cases of Prostate Cancer
    • 3.5.6. Diagnosed Five-Year Prevalent Cases of CRPC
    • 3.5.7. Diagnosed Five-Year Prevalent Cases of Bone Metastases Among CRPC Patients
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Prostate Cancer
  • Table 2: 9MM, Sources of Prostate Cancer Diagnosed Incidence Data
  • Table 3: 9MM, Sources of Data for the Clinical Stage of Prostate Cancer at Diagnosis
  • Table 4: 9MM, Sources of Prostate Cancer Diagnosed Five-Year Prevalent Cases Data
  • Table 5: 9MM, Sources of CRPC Diagnosed Five-Year Prevalent Cases Data
  • Table 6: 9MM, Diagnosed Incident Cases of Prostate Cancer, Ages ≥40 Years, N, 2013-2023
  • Table 7: 9MM, Age-Specific Diagnosed Incident Cases of Prostate Cancer, N, Row (%), 2013
  • Table 8: 9MM, Diagnosed Five-Year Prevalent Cases of Prostate Cancer, Ages ≥40 Years, 2013-2023
  • Table 9: 9MM, Diagnosed Five-Year Prevalent Cases of CRPC, Ages ≥40 Years, 2013-2023
  • Table 10: 9MM, Diagnosed Five-Year Prevalent Cases of Bone Metastases Among CRPC Patients, Ages ≥40 Years, 2013-2023

List of Figures

  • Figure 1: 9MM, Historical Age-Standardized Prostate Cancer Diagnosed Incidence (Cases per 100,000 Population), 1998-2007
  • Figure 2: 9MM, Diagnosed Incident Cases of Prostate Cancer, Ages ≥40 Years, N, 2013-2023
  • Figure 3: 9MM, Age-Specific Diagnosed Incident Cases of Prostate Cancer, N, 2013
  • Figure 4: 9MM, Age-Standardized Diagnosed Incidence of Prostate Cancer, Ages ≥40 Years, 2013
  • Figure 5: 9MM, Percentage Distribution of Incident Cases of Prostate Cancer By Clinical Stage at Diagnosis, Ages ≥40 Years
  • Figure 6: 9MM, Diagnosed Five-Year Prevalent Cases of Prostate Cancer, Ages ≥40 Years, 2013-2023
  • Figure 7: 9MM, Diagnosed Five-Year Prevalent Cases of CRPC, Ages ≥40 Years, 2013-2023
  • Figure 8: 9MM, Diagnosed Five-Year Prevalent Cases of Bone Metastases Among CRPC Patients, Ages ≥40 Years, 2013-2023
Back to Top